These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9779877)

  • 1. The clinical pharmacology of topoisomerase I inhibitors.
    Abang AM
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel camptothecin derivatives as topoisomerase I inhibitors.
    Basili S; Moro S
    Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.
    Gao H; Zhang X; Chen Y; Shen H; Pang T; Sun J; Xu C; Ding J; Li C; Lu W
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3233-6. PubMed ID: 15913996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 9. Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin.
    Tangirala RS; Dixon R; Yang D; Ambrus A; Antony S; Agama K; Pommier Y; Curran DP
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4736-40. PubMed ID: 16140529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Camptothecin and derivatives: a new class of antitumor agents].
    Torck M; Pinkas M
    J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase I interactive agents.
    Kirstein MN; Turner PK; Stewart CF
    Cancer Chemother Biol Response Modif; 2002; 20():99-123. PubMed ID: 12703202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase I interactive agents.
    Stewart CF
    Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan in advanced colorectal cancer.
    Creemers GJ
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-42-S20-48. PubMed ID: 9425960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
    Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
    Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
    Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
    Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
    Holden JA; Wall ME; Wani MC; Manikumar G
    Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.